Beruflich Dokumente
Kultur Dokumente
Probiotics and health: new facts and ideas Philippe Marteau*, Philippe Seksik and Raymond Jian
Many trials on probiotics are now published that use established methods to demonstrate their clinical efficacy. Convincing progress has been made in the field of inflammatory bowel disease and allergy prevention in infants. Experimental studies show clear differences (and even sometimes opposite effects) between apparently closely related probiotics and suggest new mechanisms for the observed effects, such as immunostimulation by bacterial DNA and interaction with Tolllike receptors and dendritic cells in the gastrointestinal tract.
Addresses Gastroenterology Department, European Hospital Georges Pompidou, Assistance Publique des Hpitaux de Paris & Paris V University, France *e-mail: philippe.marteau@egp.ap-hop-paris.fr Current Opinion in Biotechnology 2002, 13:486489 0958-1669/02/$ see front matter 2002 Elsevier Science Ltd. All rights reserved. Abbreviations IL-10 interleukin 10 ISS-DNA immunostimulatory DNA sequence RCT randomized controlled trial
response in the intestinal mucosa and play a pivotal immunoregulatory role in the balance of T helper cells Th1, Th2 and Th3. Christensen et al. [4] showed that different species of lactobacilli exert very different activation patterns on the dendritic cells. Furthermore, Lactobacillus reuteri DSM12246 inhibited the activities of the other species. Clearly, not all probiotics share the same immunomodulating properties and can even have opposite effects on some parameters. Moreover, in this model the dose of probiotics also strongly influenced the nature of the immune response [4], which leaves us with new questions. It has been recently discovered that bacterial DNA contains immunostimulatory sequences (ISS-DNA), especially non-methylated CpG motifs, which interact with Toll-like receptor-9 of epithelial cells; these sequences are potent activators of the innate immunity and exhibit anti-apoptotic properties in the mucosa [5]. Rachmilewitz et al. [5] showed that the administration of ISS-DNA was beneficial for the colonic mucosa in mice with chemically induced colitis. They then showed that the beneficial effect of the probiotic mixture VSL#3 (which contains three strains of bifidobacter, four strains of lactobacilli and a Streptococcus thermophilus) on this colitis model was derived from its DNA, as VSL genomic unmethylated DNA was effective whereas VSL methylated DNA and calf thymus DNA were ineffective [6]. These interesting and original results open avenues for the discovery of new treatments of inflammatory bowel disease and also demonstrate unsuspected mechanisms for some of the effects of probiotics. Madsen et al. [7] recently showed that bacterial VSL#3 DNA downregulated proinflammatory cytokine secretion by attenuation of the NF-B pathway in intestinal epithelial cells.
Introduction
Probiotics have been defined as non-pathogenic microorganisms that, when ingested, exert a positive influence on host health or physiology [1]. Many physicians have long been sceptical about their efficacy, as evidence for their efficacy was low and information on the stability of the strains in the products and their survival in the gastrointestinal tract was often lacking. However, a pharmacological approach has now been used to assess the effects and pharmacokinetics [2], and both scientists and health providers are showing renewed interest. Before 1990, 22 articles on probiotics were quoted in the Medline library, whereas more than 1000 have been published in the past ten years, including more than 200 in the first six months of this year. We now know that the pharmacokinetics of probiotics varies between strains and that many are indeed effective, as shown by positive double-blind randomized controlled trials (RCTs). Probably the most interesting and unexpected data were produced in the past few years in the field of immunomodulation with probiotics: treatment of allergic diseases or inflammatory bowel diseases. We summarize here recent data and ideas.
Probiotics and health: new facts and ideas Marteau, Seksik and Jian
487
patients versus 94% in the placebo-treated patients [9]. Interestingly, VSL#3 increased the tissue levels of interleukin 10 (IL-10) in these patients [10]. The same authors studied the effects of VSL#3 in the prevention of pouchitis [11]. Forty patients who had colectomy and ileo-pouch anal anastomosis for ulcerative colitis were randomized to receive either VSL#3 or placebo immediately after surgery and for one year. Pouchitis occurred in 10% of the patients in the VSL#3 group versus 40% in the placebo group (p <0.01). Three RCTs strongly suggested that Escherichia coli strain Nissle 1917 is as effective as mesalazine (i.e. the standard treatment) in preventing relapse of ulcerative colitis. The first two trials were criticized on the basis that the follow up was too short in the first study and that mesalazine was poorly effective in the control group [12,13]. However, the third trial was more conclusive; 222 patients with ulcerative colitis were treated for one year with mesalazine or E. coli Nissle 1917. The relapse rate at 1 year was 36.4% in the probiotic group versus 33% in the standard treatment group and the statistical analysis showed equivalence of the two treatments [14].
488
Food biotechnology
modified the genome of a Lactococcus lactis strain to make it produce high levels of IL-10. Intragastric administration of this IL-10-secreting probiotic caused a 50% reduction in mice with colitis induced with dextran sodium sulfate and prevented the onset of colitis in IL-10 knockout mice (two models of inflammatory bowel disease). Thus, the probiotic vector could provide a way to deliver the active ingredient (IL-10) at the site of inflammation. Other probiotics carrrying different immunomodulating molecules are currently being tested (e.g. superoxide dismutase, trefoil peptides). As Crohns disease mainly affects the distal ileum and colon in humans, a probiotic vector with good pharmacokinetics to this target should be selected for future trials.
7.
Madsen K, Jijon H, Yeung H, McKaigney C, De Simone C: DNA from probiotic bacteria exerts anti-inflammatory actions on epithelial cells by inhibition of NFB. Gastroenterology 2002, 122:abstract 546.
Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, Poggioli G, Miglioli M, Campieri M: Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000, 119:305-309. A well-designed double-blind placebo-controlled study showing that a probiotic preparation is very effective in the treatment of chronic relapsing pouchitis (an inflammatory bowel disease that occurs in humans after ileoanal anastomosis and in which the endogenous flora is thought to have a role). 9. Mimura T, Rizzello F, Schreiber S, Talbot IC, Nicholls R, Gionchetti P, Campieri M, Kamm M: Once daily high dose probiotic therapy maintains remission and improved quality of life in patients with recurrent or refractory pouchitis: a randomized, placebocontrolled double-blind trial. Gastroenterology 2002, 122:abstract 667.
8.
Conclusions
There is now real evidence that probiotics significantly influence health; however, they are not a panacea. Negative trials have also been published and should be encouraged, as one might learn from them and because no information should be hidden. New molecular tools, especially DNA microarray techniques, will allow us to further our understanding of how commensal or exogenous microorganisms modulate the expression of genes involved in several important intestinal functions including immunity.
10. Ulisse S, Gionchetti P, DAlo S, Russo FP, Pesce I, Ricci G, Rizzello F, Helwig U, Cifone MG, Campieri M, De Simone C: Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. Am J Gastroenterol 2001, 96:2691-2699. 11. Gionchetti P, Rizzello F, Venturi A, Helwig U, Amadini C, Lammers KM, Ugolini F, Poggioli G, Campieri M: Prophylaxis of pouchitis onset with probiotic therapy: a double blind, placebo controlled trial. Gastroenterology 2000, 118:G1214. 12. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M: Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997, 1:853-858. 13. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT: Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999, 354:635-639. 14. Kruis W, Fric P, Stolte M and the Mutaflor study group: Maintenance of remission in ulcerative colitis is equally effective with Escherichia coli Nissle 1917 and with standard mesalamine. Gastroenterology 2001, 120:A139. 15. Isolauri E, Arvola T, Sutas Y, Moilanen E, Salminen S: Probiotics in the management of atopic eczema. Clin Exp Allergy 2000, 30:1604-1610. 16. Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E: Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001, 357:1076-1079. This double-blind randomized placebo-controlled study shows that probiotic administration in mothers before birth, during lactation and in infants significantly decreases the risk of developing atopic eczema in the first two years of life. This result is in keeping with the theory that an excessive hygiene (or a too low bacterial priming of the immune system) in infancy is associated with an increased risk of allergy. 17. Rautava S, Kalliomaki M, Isolauri E: Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic disease in the infant. J Allergy Clin Immunol 2002, 109:119-121.
2.
Hooper LV, Wong MH, Thelin A, Hansson L, Falk PG, Gordon JI: Molecular analysis of commensal host-microbial relationships in the intestine. Science 2001, 291:881-884. This paper shows that commensal bacteria modulate the expression of some of the host genes involved in several important intestinal functions, including mucosal barrier fortification. These findings provide perspectives about the interactions between resident or ingested microorganisms and their hosts. 4. Christensen HR, Frokiaer H, Pestka JJ: Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells. J Immunol 2002, 168:171-178.
3.
Rachmilewitz D, Karmeli F, Takabayashi K, Hayashi T, Leider-Trejo L, Lee J, Leoni LM, Raz E: Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology 2002, 122:1428-1441. Immunostimulatory DNA sequences (ISS-DNA) from bacteria were shown for the first time to decrease inflammation in several models of inflammatory bowel disease in rodents (dextran sodium sulfate-induced colitis and hapteninduced colitis in Balb c mice, and spontaneous colitis occurring in IL-10 knockout mice). The ISS-DNA inhibited the induction of colonic proinflammatory cytokines and chemokines and suppressed the induction of colonic matrix metalloproteinases. As the gastrointestinal tract, especially the ileum and the colon, is exposed to bacterial DNA, these findings suggest a physiological, anti-inflammatory role for immunostimulatory DNA from endogenous bacteria in the gastrointestinal tract. 6. Rachmilewitz D, Karmeli F, Takabayashi K, Hayashi T, Raz E: Amelioration of experimental colitis by probiotics is due to the immunostimulatory effect of its DNA. Gastroenterology 2002, 122:abstract T1004.
5.
18. Kirjavainen PV, Apostolou E, Arvola T, Salminen SJ, Gibson GR, Isolauri E: Characterizing the composition of intestinal microflora as a prospective treatment target in infant allergic disease. FEMS Immunol Med Microbiol 2001, 32:1-7. 19. Apostolou E, Pelto L, Kirjavainen PV, Isolauri E, Salminen SJ, Gibson GR: Differences in the gut bacterial flora of healthy and milk-hypersensitive adults, as measured by fluorescence in situ hybridization. FEMS Immunol Med Microbiol 2001, 30:217-221. 20. Helin T, Haahtela S, Haahtela T: No effect of oral treatment with an intestinal bacterial strain, Lactobacillus rhamnosus (ATCC 53103), on birch-pollen allergy: a placebo-controlled double-blind study. Allergy 2002, 57:243-246. This paper shows that L. rhamnosus GG is not effective in every case of allergy, as no effect was observed in adults or teenagers with birch pollen and apple allergy. 21. Coconnier MH, Lievin V, Hemery E, Servin AL: Antagonistic activity against Helicobacter infection in vitro and in vivo by the human
Probiotics and health: new facts and ideas Marteau, Seksik and Jian
489
Lactobacillus acidophilus strain LB. Appl Environ Microbiol 1998, 64:4573-4580. 22. Cremonini F, Canducci F, Di Caro S, Santarelli L, Armuzzi A, Gasbarrini G, Gasbarrini A: Helicobacter pylori treatment: a role for probiotics? Dig Dis 2001, 19:144-147. 23. Sakamoto I, Igarashi M, Kimura K, Takagi A, Miwa T, Koga Y: Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans. J Antimicrob Chemother 2001, 47:709-710. 24. Felley CP, Corthesy-Theulaz I, Rivero JL, Sipponen P, Kaufmann M, Bauerfeind P, Wiesel PH, Brassart D, Pfeifer A, Blum AL, Michetti P: Favourable effect of an acidified milk (LC-1) on Helicobacter pylori gastritis in man. Eur J Gastroenterol Hepatol 2001, 13:25-29. 25. Mukai T, Asasaka T, Sato E, Mori K, Matsumoto M, Ohori H: Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS Immunol Med Microbiol 2002, 32:105-110. 26. Vesa TH, Marteau P, Korpela R: Lactose intolerance. J Am Coll Nutr 2000, 19(2 Suppl):165S-175S.
Drouault S, Juste C, Marteau P, Renault P, Corthier G: Oral treatment with Lactococcus lactis expressing Staphylococcus hyicus lipase enhances lipid digestion in pigs with induced pancreatic insufficiency. Appl Environ Microbiol 2002, 68:3166-3168. This paper shows that bacteria that are lysed by bile in the upper small intestine may be used to transport enzymes and cure disease. L. lactis that was genetically modified to contain high levels of lipase helped lipid digestion in a pig model with pancreatic insufficiency. Clinical applications can be expected, especially in patients with cystic fibrosis and insufficient response to classical pancreatic enzyme supplementation. Genetically modified probiotics could constitute new treatment strategies. 28. Sidhu H, Allison MJ, Chow JM, Clark A, Peck AB: Rapid reversal of hyperoxaluria in a rat model after probiotic administration of Oxalobacter formigenes. J Urol 2001, 166:1487-1491. 29. Pouwels PH, Vriesema A, Martinez B, Tielen FJ, Seegers JF, Leer RJ, Jore J, Smit E: Lactobacilli as vehicles for targeting antigens to mucosal tissues by surface exposition of foreign antigens. Methods Enzymol 2001, 336:369-389. 30. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, Fiers W, Remaut E: Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000, 289:1352-1355.
27.